The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.
APOE ε2 is associated with intact cognition but increased Alzheimer pathology in the oldest old
Open accessAbstract
BACKGROUND: Many studies have examined the role of APOE genotype in the development of dementia, specifically Alzheimer disease (AD). The APOE epsilon4 allele (APOE4) is a risk factor for both clinical and neuropathologic AD whereas the APOE epsilon2 allele (APOE2) seems to be protective. This would predict, even with advanced age, that APOE2 carriers would be less likely to have dementia and less likely to meet pathologic criteria for AD. METHODS: The first 85 genotyped participants from The 90+ Study to come to autopsy were included. All-cause dementia (using DSM-IV criteria) and AD (using National Institute of Neurological and Communicative Disorders and Stroke-Alzheimer's Disease and Related Disorders Association criteria) diagnoses were made by consensus conference using all available information including neuropsychological testing, neurologic examination, and medical records. Neuropathologic examination included Braak and Braak staging for plaques and tangles and diagnosis of neuropathologic AD using National Institute on Aging-Reagan criteria. RESULTS: Across all genotypes, 58.5% of subjects were diagnosed with clinical dementia (81% of dementia was AD) and 50.0% met neuropathologic criteria for AD. Compared to those with an APOE epsilon3/epsilon3 genotype (APOE3/3), APOE4 carriers were more likely to be diagnosed with dementia (odds ratio [OR] = 12.2, 95% confidence interval [CI] = 1.5-102.0), whereas APOE2 carriers were not (OR = 0.3, 95% CI = 0.1-1.3). Surprisingly, both APOE4 (OR = 4.6, 95% CI = 1.3-16.5) and APOE2 (OR = 7.8, 95% CI = 1.5-40.2) carriers were more likely to meet neuropathologic criteria for AD than those with APOE3/3 genotype. CONCLUSIONS: In the oldest old, the presence of the APOE epsilon2 allele (APOE2) was associated with a somewhat reduced risk of dementia, but paradoxically was associated with increased Alzheimer disease (AD) neuropathology. Therefore, oldest old APOE2 carriers may have some mechanism that contributes to the maintenance of cognition independently of the formation of AD pathology.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This APOE2induced deposition of diffuse plaques is novel in a mouse model and consistent with the previous work by Dr. C. Kawas and co-workers (54,55) who report that increased diffuse plaques are associated with APOE2 in cognitively normal subjects compared with compact plaques in APOE4 AD patients from the oldest of the old study.”
From APOE4-specific Changes in Aβ Accumulation in a New Transgenic Mouse Model of Alzheimer Disease (2012) · cites this paper as [54]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“It remains unclear whether apoE2 exerts its protective effect through modulating Aβ aggregation or an alternative mechanism that is independent of amyloid plaque formation (Berlau et al., 2009).”
From The role of apolipoprotein E in Alzheimer's disease (2009) · cites this paper as Berlau et al., 2009
In the citing paper
“After all, many with plaques will remain asymptomatic for years or even decades, and perhaps some will never develop symptoms [241].”
From The Alzheimer’s disease mitochondrial cascade hypothesis: progress and perspectives (2014) · cites this paper as [241]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915
Neuropathological stageing of Alzheimer-related changes.
Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123
Mirra, S. S., Heyman, A., McKeel, D., Sumi, S. M., Crain, B. J., Brownlee, L. M., Vogel, F. S., Hughes, J. P., Belle, G. V., Berg, L., et al. (1991) · Neurology · doi:10.1212/wnl.41.4.479 · Cited by 4,961
Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease
Corder, E. H., Saunders, A. M., Risch, N. J., Strittmatter, W. J., Schmechel, D. E., Gaskell, P. C., Rimmler, J. B., Locke, P. A., Conneally, P. M., Schmader, K. E., et al. (1994) · Nature Genetics · doi:10.1038/ng0694-180 · Cited by 1,920
HYMAN, B. T., & TROJANOWSKI, J. Q. (1997) · Journal of Neuropathology and Experimental Neurology · doi:10.1097/00005072-199710000-00002 · Cited by 1,542
Neuropathology of older persons without cognitive impairment from two community-based studies
Bennett, D. A., Schneider, J. A., Arvanitakis, Z., Kelly, J. F., Aggarwal, N. T., Shah, R. C., & Wilson, R. S. (2006) · Neurology · doi:10.1212/01.wnl.0000219668.47116.e6 · Cited by 1,336
The prevalence of dementia: A quantitative integration of the literature
Jorm, A. F., Korten, A. E., & Henderson, A. S. (1987) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1987.tb02906.x · Cited by 1,301
Katzman, R., Terry, R., DeTeresa, R., Brown, T., Davies, P., Fuld, P., Renbing, X., & Peck, A. (1988) · Annals of Neurology · doi:10.1002/ana.410230206 · Cited by 1,225
Consensus Recommendations for the Postmortem Diagnosis of Alzheimer’s Disease
(1997) · Neurobiology of Aging · doi:10.1016/s0197-4580(97)00057-2 · Cited by 981
ApoE Promotes the Proteolytic Degradation of Aβ
Jiang, Q., Lee, C. Y. D., Mandrekar, S., Wilkinson, B., Cramer, P., Zelcer, N., Mann, K., Lamb, B., Willson, T. M., Collins, J. L., et al. (2008) · Neuron · doi:10.1016/j.neuron.2008.04.010 · Cited by 876
Cited by
Sorted by citations
Items 101–184 of 184
Diagnosis and Management of Cognitive Concerns in the Oldest-Old
Borders, C. B., & Sajjadi, S. A. (2021) · Current Treatment Options in Neurology · doi:10.1007/s11940-021-00665-5 · Cited by 17
Wang, H.-Y., Trocmé, C., Stucky, A., Shah, S. M., Kvasic, J., Khan, A., Morain, P., Guignot, I., Bouguen, E., Deschet, K., et al. (2017) · Alzheimer s Research & Therapy · doi:10.1186/s13195-017-0280-8 · Cited by 14
RetractedHohman, T. J., Dumitrescu, L. C., Oksol, A., Wagener, M. A., Gifford, K. A., Jefferson, A. L., & Initiative, A. D. N. (2017) · PLoS ONE · doi:10.1371/journal.pone.0188501 · Cited by 15
Saraceno, G. F., Abrego-Guandique, D. M., Cannataro, R., Caroleo, M. C., & Cione, E. (2024) · BioMedInformatics · doi:10.3390/biomedinformatics4010033 · Cited by 13
Kopeć, K., Koziorowski, D., & Szlufik, S. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26157552 · Cited by 15
Interaction Between APOE Genotype and Diabetes in Longevity
Shinohara, M., Suzuki, K., Bu, G., & Sato, N. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-210125 · Cited by 12
Kulminski, A. M., Philipp, I., Loika, Y., He, L., & Culminskaya, I. V. (2021) · Alzheimer s & Dementia · doi:10.1002/alz.12413 · Cited by 11
Velez, J. I., Lopera, F. J., Creagh, P. K., Piñeros-Hernández, L. B., Das, D., Cervantes-Henríquez, M. L., Acosta-López, J. E., Isaza-Ruget, M. A., Espinosa, L. G., Easteal, S., et al. (2018) · Molecular Neurobiology · doi:10.1007/s12035-018-1298-z · Cited by 12
McFall, G. P., Bäckman, L., & Dixon, R. A. (2019) · Current Alzheimer Research · doi:10.2174/1567205016666190315094452 · Cited by 11
Ren, D., López, O. L., Lingler, J. H., & Conley, Y. P. (2020) · Journal of the American Geriatrics Society · doi:10.1111/jgs.16337 · Cited by 11
Neocortical β‐amyloid area is associated with dementia and APOE in the oldest‐old
Berlau, D. J., Corrada, M. M., Robinson, J. L., Geser, F., Arnold, S. E., Lee, V. M. ‐., Kawas, C. H., & Trojanowski, J. Q. (2013) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2012.11.011 · Cited by 11
Espay, A. J., & Stecher, B. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108888202 · Cited by 10
Hua, L., Gao, F., Xia, X., Guo, Q., Zhao, Y., Huang, S., & Yuan, Z. (2023) · Communications Biology · doi:10.1038/s42003-023-04952-6 · Cited by 9
Wesselman, L. M. P., Schild, A., Hooghiemstra, A. M., Meiberth, D. U., Drijver, A. J., van Leeuwenstijn‐Koopman, M., Prins, N. D., Brennan, S., Scheltens, P., Jessen, F., et al. (2020) · The Journal of Prevention of Alzheimer s Disease · doi:10.14283/jpad.2020.9 · Cited by 9
Physics of Protein Aggregation in Normal and Accelerated Brain Aging
Espay, A. J., Sturchio, A., Imarisio, A., Hill, E. J., Williamson, B. J., Montemagno, K. T., Hoffmann, C., Roy, H. L., Milovanović, D., & Manfredsson, F. P. (2025) · BioEssays · doi:10.1002/bies.70030 · Cited by 9
Cancer and Vascular Comorbidity Effects on Dementia Risk and Neuropathology in the Oldest-Old
Lachner, C., Day, G. S., Camsari, G. B., Kouri, N., Ertekin‐Taner, N., Boeve, B. F., Labuzan, S. A., Lucas, J. A., Thompson, E. A., Siddiqui, H., et al. (2022) · Journal of Alzheimer s Disease · doi:10.3233/jad-220440 · Cited by 8
Savignac, C., Villeneuve, S., Badhwar, A., Saltoun, K., Shafighi, K., Zajner, C., Sharma, V., Taliun, S. A. G., Farhan, S. M. K., Poirier, J., et al. (2022) · PLoS Biology · doi:10.1371/journal.pbio.3001863 · Cited by 11
Caselli, R. J. (2012) · Alzheimer s Research & Therapy · doi:10.1186/alzrt123 · Cited by 7
Kim, S., Kim, K., Nho, K. T., Myung, W., & Won, H. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-200671 · Cited by 7
APOE ε2 and presymptomatic stage Alzheimer disease
Caselli, R. J., & Dueck, A. C. (2010) · Neurology · doi:10.1212/wnl.0b013e3181ff94f7 · Cited by 7
Liang, J. J., Pitsillou, E., Man, A. Y. L., Madzima, S., Bresnehan, S. M., Nakai, M. E., Hung, A., & Karagiannis, T. C. (2020) · Computational Biology and Chemistry · doi:10.1016/j.compbiolchem.2020.107271 · Cited by 6
Lelos, M. J. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-818084-6.00002-7 · Cited by 5
Resilience mechanisms underlying Alzheimer’s disease
Chew, C. S., Jy, L., Ng, K. Y., Koh, R. Y., & Chye, S. M. (2025) · Metabolic Brain Disease · doi:10.1007/s11011-024-01507-4 · Cited by 6
Britton, M. K., Jensen, G., Edden, R. A. E., Puts, N. A. J., Nolin, S. A., Merritt, S. S., Rezaei, R. F., Forbes, M. A., Johnson, K. J., Bharadwaj, P. K., et al. (2025) · Translational Psychiatry · doi:10.1038/s41398-025-03302-w · Cited by 5
Liu, X., Zeng, Q., Luo, X., Li, K., Hong, H., Wang, S., Guan, X., Wu, J., Zhang, R., Zhang, T., et al. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.591347 · Cited by 5
Effect of APOE Genotype on Synaptic Proteins in Earlier Adult Life
Sinclair, L. I., & Love, S. (2017) · Journal of Alzheimer s Disease · doi:10.3233/jad-170316 · Cited by 4
Zhang, C., Ren, H., Li, M., Wang, Q., Deng, W., Guo, W., Lei, W., Xiang, B., Zhao, L., Ma, X., et al. (2015) · Neuroscience Bulletin · doi:10.1007/s12264-014-1515-3 · Cited by 4
Superior short-term memory in APOE ε2 carriers across the age range
Zokaei, N., Alexander G Board, Slavkova, E., Mackay, C. E., Nobre, A. C., & Masud Husain, B. (2020) · Behavioural Brain Research · doi:10.1016/j.bbr.2020.112918 · Cited by 4
Cammisuli, D. M., Bellocchio, V., Milesi, A., Aiello, E. N., Poletti, B., Verde, F., Silani, V., Ticozzi, N., Marchesi, G., Granese, V., et al. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13185447 · Cited by 3
Jiraanont, P., Wang, J. Y., Durbin-Johnson, B., Hwang, Y. H., Hessl, D. R., Rivera, S. M., Hagerman, R. J., & Tassone, F. (2026) · Neurobiology of Disease · doi:10.1016/j.nbd.2026.107292 · Cited by 3
Yee, A., Tsui, N. B. Y., Kwan, R. Y. C., Leung, A. Y. M., Lai, C. K. Y., Chung, T., Lau, J. Y. N., Fok, M., Dai, D., & Lau, L. T. (2021) · Current Alzheimer Research · doi:10.2174/1567205018666210324111401 · Cited by 3
Espay, A. J., Vizcarra, J. A., Marsili, L., Lang, A. E., Sardi, S. P., & Leverenz, J. B. (2020) · Neurology · doi:10.1212/wnl.0000000000008822 · Cited by 3
Savignac, C., Villeneuve, S., Badhwar, A., Saltoun, K., Shafighi, K., Zajner, C., Sharma, V., Taliun, S. A. G., Farhan, S. M. K., Poirier, J., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.03.15.484482 · Cited by 3
Pathology vs pathogenesis: Rationale and pitfalls in the clinicopathology model of neurodegeneration
Donadio, V. A., Sturchio, A., Rizzo, G., Abu‐Rumeileh, S., Liguori, R., & Espay, A. J. (2023) · Handbook of clinical neurology · doi:10.1016/b978-0-323-85538-9.00001-8 · Cited by 2
Whole-genome sequencing reveals the impact of lipid pathway and APOE genotype on brain amyloidosis
Patel, M., Pottier, C. P., Fan, K.-H., Cetin, A., Johnson, M., Ali, M., Liu, M., Gorijala, P., Budde, J., Shi, R., et al. (2025) · Human Molecular Genetics · doi:10.1093/hmg/ddaf017 · Cited by 2
Symptomatic vs. Disease-Modifying Therapies
Espay, A. J., & Stecher, B. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108888202.011 · Cited by 2
Gene polymorphisms of CETP and apolipoprotein E in elderly subjects with cognitive impairment
Niculescu, L. S., Toma, L., Ianas, O., & Sima, A. V. (2012) · Open Life Sciences · doi:10.2478/s11535-012-0042-3 · Cited by 2
Apolipoprotein E ε4 is superior to apolipoprotein E ε2 in predicting cognitive scores over 30 months
Regal, P. J., Nair, B., & Hetherington, E. J. (2013) · Clinical Interventions in Aging · doi:10.2147/cia.s47485 · Cited by 2
Characterization of APOE Christchurch carriers in 455,306 UK Biobank participantsPreprint
He, K., Khramtsova, E. A., Cabrera‐Socorro, A., Zhang, Y., Li, S., Sarver, B. A. J., Smets, B., Li, Q. S., Muynck, L. D., Parrado, A., et al. (2022) · medRxiv · doi:10.1101/2022.12.05.22283048 · Cited by 2
Evaluating the association of APOE genotype and cognitive resilience in SuperAgersPreprint
Durant, A., Mukherjee, S., Lee, M. L., Choi, S., Scollard, P., Klinedinst, B. S., Trittschuh, E. H., Mez, J. B., Farrer, L. A., Gifford, K. A., et al. (2025) · medRxiv · doi:10.1101/2025.01.07.25320117 · Cited by 2
Loika, Y., Webster, S., Loiko, E., & Kulminski, A. M. (2024) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1002/dad2.70016 · Cited by 1
Evaluating the association of apolipoprotein E genotype and cognitive resilience in SuperAgers
Durant, A., Mukherjee, S., Lee, M. L., Choi, S., Scollard, P., Klinedinst, B. S., Trittschuh, E. H., Mez, J., Farrer, L. A., Gifford, K. A., et al. (2026) · Alzheimer s & Dementia · doi:10.1002/alz.71024 · Cited by 6
Longevity and cognitive resilience in a Colombian family carrying the APOE ε2 variant
Guerrero, A., Galvis-Garrido, N. D., Bocanegra, Y., Vásquez, D., Becerra, J. C., Zuluaga, Y., Baena, A. Y., Zubiri, V., Alzate, D., Osorio, L., et al. (2026) · Journal of Alzheimer s Disease · doi:10.1177/13872877261449392 · Cited by 1
Colbeth, H., Corrada, M. M., Mungas, D., Gilsanz, P., George, K. M., Gaied, R., Kawas, C. H., DeCarli, C. S., & Whitmer, R. A. (2026) · The Lancet Healthy Longevity · doi:10.1016/j.lanhl.2026.100882 · Cited by 1
Role of APOE ɛ4 and ɛ2 With Longitudinal Cognitive Decline Among Those With Exceptional Longevity
Colbeth, H., Posis, A. I. B., Rizvi, B. M., DeCarli, C. S., Glymour, M. M., George, K. M., Corrada, M. M., Gilsanz, P., & Whitmer, R. A. (2026) · Neurology · doi:10.1212/wnl.0000000000218596 · Cited by 1
Stephens, G. S., You, J. C., Fu, C.-H., & Chin, J. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-809324-5.21126-7 · Cited by 1
Huang, X., Dong, S., Zhen, J., Zhang, H., Lin, T., Zeng, Y. H., Halm‐Lutterodt, N. V., & Yuan, L. (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00071 · Cited by 1
Disease Subtypes: The Promise and the Fallacy
Espay, A. J., & Stecher, B. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108888202.006 · Cited by 1
Compensating for Alzheimer lesions
Lippa, C. F. (2009) · Neurology · doi:10.1212/wnl.0b013e3181b61b4c · Cited by 1
Overexpression of HIF-2α in Protected Regions of Alzheimer’s disease Resilient CasesPreprint
Mitri, V. (2020) · medRxiv · doi:10.1101/2020.08.27.20180331 · Cited by 1
Hua, L., Gao, F., Xia, X., Guo, Q., Zhao, Y., & Yuan, Z. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.11.14.516364 · Cited by 1
Vivian, L., Bruscato, N. M., Werle, B. M., de Carli, W., Soares, R. A. G., Santos, P. C. D. L., & Moriguchi, E. H. (2020) · Arquivos Brasileiros de Cardiologia · doi:10.36660/abc.20190263
PET and SPECT Studies of Ageing and Cardiovascular Risk Factors for Alzheimer’s Disease
Busatto, G. F., Tamashiro-Duran, J. H., de Toledo, T. C., Ferreira, L. K., Duran, F., & Buchpiguel, C. A. (2014) · Springer eBooks · doi:10.1007/978-3-642-54307-4_21
New Thinking on the Etiology and Pathogenesis of Late‐Onset Alzheimer′s Disease
Hudson, A. P., Balin, B. J., Crutcher, K. A., & Robinson, S. R. (2011) · International Journal of Alzheimer s Disease · doi:10.4061/2011/848395 · Cited by 1
Chiang, G. C.-Y., Wang, Z., & Schuff, N. W. (2012)
Santos, P. P. (2016) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/d.5.2016.tde-24102016-142111
The Interaction Between Gamma-Secretase And Its Inhibitors And Modulators – Structural Insights
Gertsik, N. (2016) · eCommons (Cornell University)
Saeed, U. (2018) · TSpace (University of Toronto)
A study of the global effects of Apolipoprotein E using lipidomics
Hawksworth, J. I. (2019) · ORCA Online Research @Cardiff (Cardiff University)
The Hypothesis That Refuses to Die
Espay, A. J., & Stecher, B. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108888202.012
Li, W., Yue, L., Li, X., & Xiao, S. (2021) · Research Square · doi:10.21203/rs.3.rs-504367/v1
Effects of Apolipoprotein E Gene and Sex On Serum Lipid Profiles in Alzheimer's DiseasePreprint
Fu, J., Huang, Y. Y., Bao, T., Ou, R., Wei, Q., Chen, Y., Yang, J., Chen, X., & Shang, H. (2021) · Research Square · doi:10.21203/rs.3.rs-1140484/v1
Espay, A. J., & Stecher, B. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108888202.020
Espay, A. J., & Stecher, B. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108888202.013
Disease “Redefinition”: A Tough Pill to Swallow
Espay, A. J., & Stecher, B. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108888202.005
Espay, A. J., & Stecher, B. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108888202.008
The Shaky Six and the “Second Reality”
Espay, A. J., & Stecher, B. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108888202.003
Predictions for the 2020s and Beyond
Espay, A. J., & Stecher, B. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108888202.017
The Scientific and Lay Narratives
Espay, A. J., & Stecher, B. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108888202.014
Note Added at Press Time – Reviving LOF
Espay, A. J., & Stecher, B. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108888202.019
Espay, A. J., & Stecher, B. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108888202.001
Espay, A. J., & Stecher, B. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108888202.015
Espay, A. J., & Stecher, B. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108888202.018
Current awareness in geriatric psychiatry
(2009) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.2118
The Moonshot: Population-Based Studies of Aging
Espay, A. J., & Stecher, B. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108888202.016
Espay, A. J., & Stecher, B. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108888202.002
Espay, A. J., & Stecher, B. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108888202.010
Espay, A. J., & Stecher, B. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108888202.004
Biomarkers: The Promise and the Fallacy
Espay, A. J., & Stecher, B. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108888202.009
Espay, A. J., & Stecher, B. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108888202.007
Espay, A. J., & Stecher, B. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108888202.021
Peter, J., & Klöppel, S. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-397025-1.00073-7 · Cited by 1
APOE2 Heterozygosity Reduces Hippocampal Soluble Amyloid-β42 Levels in Non-Hyperlipidemic Mice
Valencia‐Olvera, A. C., Balu, D., Moore, A., Shah, M., Ainis, R., Xiang, B., Saleh, Y., Cai, D., LaDu, M. J., & Tai, L. M. (2024) · Journal of Alzheimer s Disease · doi:10.3233/jad-231210
Savignac, C., St‐Onge, F., Villeneuve, S., Badhwar, A., Taliun, S. A. G., Farhan, S., Geddes, M. R., Medina, Y. I., Poirier, J., Spreng, R. N., et al. (2026) · Cell Reports Medicine · doi:10.1016/j.xcrm.2026.102943
Metadata
- Authors
- Berlau, D. J., Corrada, M. M., Head, E., & Kawas, C. H.
- Affiliations
- University of California, Irvine (US)
- From the Institute of Brain Aging and Dementia (D.J.B., M.M.C., E.H., C.H.K.) and Departments of Neurology (M.M.C., E.H., C.H.K.) and Neurobiology & Behavior (C.H.K.), University of California, Irvine.
- Venue
- Neurology
- Published
- 2009-03-03
- Volume
- 72
- Issue
- 9
- Pages
- 829-834
- ISSN
- 0028-3878 (ISSN-L)
- 1526-632X
- PMC
- PMC2667799
- OpenAlex
- W2092189536
- Cited by
- 185
- References
- 43
- Citations by year
- 2026: 6 · 2025: 6 · 2024: 6 · 2023: 2 · 2022: 8 · 2021: 15 · 2020: 35 · 2019: 10 · 2018: 9 · 2017: 10 · 2016: 9 · 2015: 9 · 2014: 7 · 2013: 10 · 2012: 13
- FWCI
- 8.84
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Neurology (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- eScholarship (California Digital Library) (submittedVersion, cc-by)
- Funders
- National Institute on Aging (R01 AG21055, R01AG021055, P50AG016573, T32AG000096)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Complementary and alternative medicine › Medicinal Plants and Neuroprotection
- Keywords
- APOE ε2, APOE ε4, APOE genotype, Alzheimer's disease, dementia, oldest old, cognitive function, neuropathology, amyloid plaques, neurofibrillary tangles, Braak staging, genetic risk factors
- MeSH terms
- Age Factors, Aged, Aged, 80 and over, Alzheimer Disease, Brain, Cognition, Female, Humans, Longitudinal Studies, Male, Neurons, Prospective Studies, Apolipoprotein E2
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
